These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38223578)

  • 1. Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials.
    Jie Y; Youchun L; Jingxiang C
    Afr Health Sci; 2023 Jun; 23(2):402-408. PubMed ID: 38223578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
    Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.
    Mu LY; Li SQ; Tang LX; Li R
    Clinics (Sao Paulo); 2021; 76():e2409. PubMed ID: 34133478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis.
    Weinberg EM; Curry MP; Frenette CT; Regenstein FG; Schiff ER; Goodman ZD; Robinson JM; Chan JL; Imperial JC; Reddy KR
    Liver Transpl; 2021 Apr; 27(4):568-579. PubMed ID: 33164276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Zhou Q; Peng Y; Chen F; Dai J
    Afr Health Sci; 2023 Mar; 23(1):614-621. PubMed ID: 37545930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
    Shiffman M; Freilich B; Vuppalanchi R; Watt K; Chan JL; Spada A; Hagerty DT; Schiff E
    Aliment Pharmacol Ther; 2019 Jan; 49(1):64-73. PubMed ID: 30430605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soy diet for nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
    Xiong P; Zhu YF
    Medicine (Baltimore); 2021 Jun; 100(22):e25817. PubMed ID: 34087824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
    Mehta G; Rousell S; Burgess G; Morris M; Wright G; McPherson S; Frenette C; Cave M; Hagerty DT; Spada A; Jalan R
    J Clin Exp Hepatol; 2018 Sep; 8(3):224-234. PubMed ID: 30302038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials.
    Xiaohui L; Jinqi L; Xiaofang X; Zhiqiang S; Renxiu N
    Afr Health Sci; 2023 Jun; 23(2):409-415. PubMed ID: 38223588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dexmedetomidine supplementation for thoracoscopic surgery: a meta-analysis of randomized controlled trials.
    Song C; Lu Q
    J Cardiothorac Surg; 2022 Apr; 17(1):70. PubMed ID: 35382835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of magnesium added to bupivacaine for arthroscopy: a meta-analysis of randomized controlled trials.
    Xiang W; Jiang L; Shi L; Jiang C; Zhou Y; Yang C
    J Orthop Surg Res; 2021 Oct; 16(1):583. PubMed ID: 34629096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial lidocaine for pain control after uterine artery embolization: a meta-analysis of randomized controlled trials.
    Liu S; Li W
    J Matern Fetal Neonatal Med; 2022 Nov; 35(21):4162-4167. PubMed ID: 33172315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of emricasan on chronic liver diseases: current data.
    Lekakis V; Cholongitas E
    Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Vitamin D Supplementation for Migraine: A Meta-Analysis of Randomized Controlled Studies.
    Zhang YF; Xu ZQ; Zhou HJ; Liu YZ; Jiang XJ
    Clin Neuropharmacol; 2021 Jan-Feb 01; 44(1):5-8. PubMed ID: 33449474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.